Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer Zebin Wang1, Shaun E

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer Zebin Wang1, Shaun E Published OnlineFirst October 8, 2018; DOI: 10.1158/0008-5472.CAN-18-1362 Cancer Translational Science Research Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer Zebin Wang1, Shaun E. Grosskurth1, Tony Cheung1, Philip Petteruti1, Jingwen Zhang1, Xin Wang1, Wenxian Wang1, Farzin Gharahdaghi1, Jiaquan Wu1, Nancy Su1, Ryan T. Howard2, Michele Mayo1, Dan Widzowski1, David A. Scott1, Jeffrey W. Johannes1, Michelle L. Lamb1, Deborah Lawson1, Jonathan R. Dry1, Paul D. Lyne1, Edward W. Tate2, Michael Zinda1, Keith Mikule1, Stephen E. Fawell1, Corinne Reimer1, and Huawei Chen1 Abstract PARP proteins represent a class of post-translational mod- subset of breast cancer cells in vitro and antitumor effects in vivo. ification enzymes with diverse cellular functions. Targeting In addition, Chk1 was identified as a specific substrate of PARPs has proven to be efficacious clinically, but exploration PARP6 and was further confirmed by enzymatic assays and of the therapeutic potential of PARP inhibition has been by mass spectrometry. Furthermore, when modification of limited to targeting poly(ADP-ribose) generating PARP, Chk1 was inhibited with AZ0108 in breast cancer cells, we including PARP1/2/3 and tankyrases. The cancer-related func- observed marked upregulation of p-S345 Chk1 accompanied tions of mono(ADP-ribose) generating PARP, including by defects in mitotic signaling. Together, these results establish PARP6, remain largely uncharacterized. Here, we report a proof-of-concept antitumor efficacy through PARP6 inhibi- novel therapeutic strategy targeting PARP6 using the first tion and highlight a novel function of PARP6 in maintaining reported PARP6 inhibitors. By screening a collection of PARP centrosome integrity via direct ADP-ribosylation of Chk1 and compounds for their ability to induce mitotic defects, we modulation of its activity. uncovered a robust correlation between PARP6 inhibition and induction of multipolar spindle (MPS) formation, which was Significance: These findings describe a new inhibitor of phenocopied by PARP6 knockdown. Treatment with AZ0108, PARP6 and identify a novel function of PARP6 in regulating a PARP6 inhibitor with a favorable pharmacokinetic profile, activation of Chk1 in breast cancer cells. Cancer Res; 78(23); potently induced the MPS phenotype, leading to apoptosis in a 6691–702. Ó2018 AACR. Introduction spontaneous tumorigenesis, although the typical consequence of multipolar mitosis is often detrimental to dividing cells (5). The presence of supernumerary centrosomes is a common To ensure successful mitosis, aneuploid cancer cells can evolve feature of solid malignant tumors, differentiating them from several mechanisms to avoid chromosome segregation errors (6). normal cells. Centrosomes normally function as the main micro- One major mechanism involves clustering and assembling mul- tubule-organizing centers (MTOC) and play an essential role tiple centrosomes into pseudo-bipolar spindles through a tightly during cellular mitosis (1). Evidence suggests that centrosome regulated process (6, 7). Disruption of this process results in abnormalities contribute to a high degree of aneuploidy in cancer multipolar mitosis and has been shown to be a therapeutic cells and are associated with advanced tumor grade (2–4). A recent strategy to specifically kill cancer cells with amplified centrosomes report indicates centrosome amplification is sufficient to promote while sparing normal cells (8, 9). The tubulin-stabilizing agent griseofulvin and its derivative GF-15, as well as the HSET/KIFC1 inhibitor AZ82, have been reported to induce formation of multipolar spindles (MPS) to selectively kill cancer cells 1 Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachu- (10–12). Through unbiased siRNA screens, members of the setts. 2Institute of Chemical Biology, Department of Chemistry, Imperial College therapeutically tractable PARPs enzyme family have also been London, London, United Kingdom. implicated in centrosome clustering and bipolar spindle forma- Note: Supplementary data for this article are available at Cancer Research tion, providing the preliminary evidence to further investigate Online (http://cancerres.aacrjournals.org/). the pharmacological inhibition of PARPs to specifically perturb Z. Wang and S.E. Grosskurth contributed equally to this article and share first mitosis in cancer cells (8, 13). authorship. PARPs are a family of 17 enzymes that catalyze the transfer of þ Corresponding Author: Huawei Chen, AstraZeneca R&D Boston, 35 Gatehouse the ADP-ribose from NAD to post-translationally modify accep- Drive, Waltham, MA, 02451. Phone: 781-839-4417; Fax. 781-839-4200; E-Mail: tor proteins. Depending on their catalytic activity, PARPs can be [email protected] further divided into poly(ADP-ribose) generating PARPs such as doi: 10.1158/0008-5472.CAN-18-1362 PARPs 1-5, catalytically inactive PARPs such as PARPs 9 and 13, Ó2018 American Association for Cancer Research. and mono(ADP-ribose) generating PARPs such as PARPs 6-8, www.aacrjournals.org 6691 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst October 8, 2018; DOI: 10.1158/0008-5472.CAN-18-1362 Wang et al. 10-12, and 14-15 (14, 15). The post-translational modification alone positive control—negative control). IC50 values were cal- of substrate proteins by PARPs has been demonstrated, for culated by fitting the percentage inhibition to a four-parameter example, by PARP1-3 to regulate numerous signaling cascades, logistic regression equation with an AstraZeneca in-house calcu- including DNA damage response, chromatin remodeling, and lation engine. transcriptional regulation, as well as by PARP5a-5b for telomere maintenance, spindle assembly, vesicular movement, and degra- Immunofluorescent multipolar spindle assay dation of the beta-catenin destruction complex (16, 17). Given Indicated cell lines were plated in 96-well plates at 7,000 cells that PARPs have functional roles in mitosis and that PARP1/2 per well and incubated at 37C overnight. The cells were treated inhibition is a successful therapeutic approach to treat homolo- with compounds ranging from 0 to 11 mmol/L for 48 hours. gous recombination defective tumors in the clinic (18, 19), The cells were fixed with 4% formaldehyde at room temperature this prompted us to perform a cell-based MPS phenotypic for 10 minutes followed with ice-cold methanol fixation for screen with compounds that have structural similarity to PARP another 10 minutes. After four washes in PBS, the cells were inhibitor scaffolds. incubated in blocking buffer for 1 hour at room temperature to Here, we report the characterization of novel small molecule reduce non-specific binding. The cells were labeled with primary PARP inhibitors that induce MPS formation in cancer cells and antibodies, 1:2,000 dilution of anti-cyclin B antibody (Thermo provide evidence that this phenotype is due to PARP6 inhibition. Fisher) and 1:4,000 dilution of anti-pericentrin antibody PARP6 is a mono (ADP-ribose) generating PARP with little (Abcam), for 16 hours at 4C. After washing with PBS four times, biological characterization. Pharmacological inhibition of PARP6 the cells were labeled with secondary antibodies, 1:200 Alexa in breast cancer cells using AZ0108 (20), an optimized inhibitor Fluor 488 anti-rabbit antibody and Alexa Fluor 594 anti-mouse developed from phenotypic screen hits, resulted in MPS forma- antibody, for 1 hour at room temperature. After washing with PBS tion, impaired cell growth, and induction of apoptosis in vitro and twice, the cells were stained with Hoechst dye for 10 minutes at in vivo. Using a high-density protein array–based ADP-ribosyla- room temperature. The cells were washed twice with PBS and then tion assay, we identified Chk1 kinase within a subset of proteins images were acquired by ImageXpress Micro (Molecular Devices) involved in regulating centrosome function that were enriched as or Operatte (PerkinElmer) High Content Screening System. direct PARP6 substrates. We confirmed PARP6 ADP-ribosylates Cyclin B label was used for scoring the mitotic cells and pericen- Chk1 directly and demonstrated Chk1 S345 phosphorylation was trin was used for scoring the centrosome number in each mitotic significantly upregulated upon PARP6 inhibition, which was cell. The percentage of increase of mitotic cells with greater than accompanied by de-activation of other mitotic proteins during 2 centrosomes compared with the DMSO control was used to the G2–M transition. Taken together, our studies demonstrate a calculate EC50 values. For CHK1 and pericentrin staining, CHK1 critical role for PARP6 in ensuring the integrity of mitosis and antibody (1:100, Cell Signaling Technology) and pericentrin provide preclinical proof-of-concept for inhibiting PARP6 as a (Abcam) antibodies were used to stain HCC1806 cells after novel cancer therapeutic strategy. AZ0108 treatment following the same protocol. Images were taken with Operetta (PerkinElmer) High Content Screening Sys- tem, and CHK1 intensity was analyzed with Harmony analysis Materials and Methods software (PerkinElmer). Chemicals and cell lines AZD2281/olaparib, AZ9482, and AZ0108 were synthesized Breast cancer cell line proliferation assays by AstraZeneca (20–22) and diluted in dimethyl sulfoxide Cell lines were sourced as previously described (23, 24) and (Sigma-Aldrich). Majority of cell lines were purchased from were cultured
Recommended publications
  • Stem Cell Factor Is Selectively Secreted by Arterial Endothelial Cells in Bone Marrow
    ARTICLE DOI: 10.1038/s41467-018-04726-3 OPEN Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow Chunliang Xu1,2, Xin Gao1,2, Qiaozhi Wei1,2, Fumio Nakahara 1,2, Samuel E. Zimmerman3,4, Jessica Mar3,4 & Paul S. Frenette 1,2,5 Endothelial cells (ECs) contribute to haematopoietic stem cell (HSC) maintenance in bone marrow, but the differential contributions of EC subtypes remain unknown, owing to the lack 1234567890():,; of methods to separate with high purity arterial endothelial cells (AECs) from sinusoidal endothelial cells (SECs). Here we show that the combination of podoplanin (PDPN) and Sca-1 expression distinguishes AECs (CD45− Ter119− Sca-1bright PDPN−) from SECs (CD45− Ter119− Sca-1dim PDPN+). PDPN can be substituted for antibodies against the adhesion molecules ICAM1 or E-selectin. Unexpectedly, prospective isolation reveals that AECs secrete nearly all detectable EC-derived stem cell factors (SCF). Genetic deletion of Scf in AECs, but not SECs, significantly reduced functional HSCs. Lineage-tracing analyses suggest that AECs and SECs self-regenerate independently after severe genotoxic insults, indicating the per- sistence of, and recovery from, radio-resistant pre-specified EC precursors. AEC-derived SCF also promotes HSC recovery after myeloablation. These results thus uncover heterogeneity in the contribution of ECs in stem cell niches. 1 The Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, New York, NY 10461, USA. 2 Department of Cell Biology, Albert Einstein College of Medicine, New York, NY 10461, USA. 3 Department of Systems and Computational Biology, Albert Einstein College of Medicine, New York, NY 10461, USA.
    [Show full text]
  • Survival Pathways That Regulate Macrophage Tec and Btk in M-CSF
    Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival This information is current as of September 26, 2021. Martin Melcher, Bernd Unger, Uwe Schmidt, Iiro A. Rajantie, Kari Alitalo and Wilfried Ellmeier J Immunol 2008; 180:8048-8056; ; doi: 10.4049/jimmunol.180.12.8048 http://www.jimmunol.org/content/180/12/8048 Downloaded from References This article cites 36 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/180/12/8048.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival1 Martin Melcher,2* Bernd Unger,2† Uwe Schmidt,3* Iiro A.
    [Show full text]
  • Redox-Mediated Regulation of the Tyrosine Kinase Zap70
    Redox-mediated regulation of the tyrosine kinase Zap70 DISSERTATION zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) genehmigt durch die Fakultät für Naturwissenschaften der Otto-von-Guericke-Universität von M.Sc. Christoph Thurm geb. am 27.06.1988 in Borna Gutachter: apl. Prof. Dr. Luca Simeoni PD Dr. rer. nat. Marcus Lettau eingereicht am: 02.02.2018 verteidigt am: 06.06.2018 Eigenständigkeitserklärung I. Eigenständigkeitserklärung Christoph Thurm Halberstädter Straße 29 39112 Magdeburg Hiermit erkläre ich, dass ich die von mir eingereichte Dissertation zu dem Thema Redox-mediated regulation of the tyrosine kinase Zap70 selbständig verfasst, nicht schon als Dissertation verwendet habe und die benutzten Hilfsmittel und Quellen vollständig angegeben wurden. Weiterhin erkläre ich, dass ich weder diese noch eine andere Arbeit zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) an anderen Einrichtungen eingereicht habe. Magdeburg, den 02.02.2018 ____________________________________ M.Sc. Christoph Thurm II ACKNOWLEDGEMENTS II. Acknowledgements Firstly, I would like to express my sincere gratitude to my supervisor Prof. Dr. Luca Simeoni. His extraordinary support during my PhD thesis together with his motivation and knowledge enabled me to pursue my dream. I could not have imagined having a better mentor. Furthermore, I would like to thank Prof. Dr. Burkhart Schraven for giving me the opportunity to work in his institute. His support, ideas, and the lively discussions promoted me to develop as a scientist. Special thanks go also to the whole AG Simeoni/Schraven - Ines, Camilla, Matthias, and Andreas - for the help with experiments, the discussions, and the fun we had. This helped to sustain also the longest days.
    [Show full text]
  • Gene Expression Studies: from Case-Control to Multiple-Population-Based Studies
    From the Institute of Human Genetics, Helmholtz Zentrum Munchen,¨ Deutsches Forschungszentrum fur¨ Gesundheit und Umwelt (GmbH) Head: Prof. Dr. Thomas Meitinger Gene expression studies: From case-control to multiple-population-based studies Thesis Submitted for a Doctoral Degree in Natural Sciences at the Faculty of Medicine, Ludwig-Maximilians-Universitat¨ Munchen¨ Katharina Schramm Dachau, Germany 2016 With approval of the Faculty of Medicine Ludwig-Maximilians-Universit¨atM ¨unchen Supervisor/Examiner: Prof. Dr. Thomas Illig Co-Examiners: Prof. Dr. Roland Kappler Dean: Prof. Dr. med. dent. Reinhard Hickel Date of oral examination: 22.12.2016 II Dedicated to my family. III Abstract Recent technological developments allow genome-wide scans of gene expression levels. The reduction of costs and increasing parallelization of processing enable the quantification of 47,000 transcripts in up to twelve samples on a single microarray. Thereby the data collec- tion of large population-based studies was improved. During my PhD, I first developed a workflow for the statistical analyses of case-control stu- dies of up to 50 samples. With large population-based data sets generated I established a pipeline for quality control, data preprocessing and correction for confounders, which re- sulted in substantially improved data. In total, I processed more than 3,000 genome-wide expression profiles using the generated pipeline. With 993 whole blood samples from the population-based KORA (Cooperative Health Research in the Region of Augsburg) study we established one of the largest population-based resource. Using this data set we contributed to a number of transcriptome-wide association studies within national (MetaXpress) and international (CHARGE) consortia.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence After Radical Prostatectomy
    Int. J. Mol. Sci. 2015, 16, 3856-3869; doi:10.3390/ijms16023856 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy Chinyere Ibeawuchi 1, Hartmut Schmidt 2, Reinhard Voss 3, Ulf Titze 4, Mahmoud Abbas 5, Joerg Neumann 6, Elke Eltze 7, Agnes Marije Hoogland 8, Guido Jenster 9, Burkhard Brandt 10 and Axel Semjonow 1,* 1 Prostate Center, Department of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: [email protected] 2 Center for Laboratory Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: [email protected] 3 Interdisciplinary Center for Clinical Research, University of Muenster, Albert-Schweitzer-Campus 1, Gebaeude D3, Domagkstrasse 3, Muenster D-48149, Germany; E-Mail: [email protected] 4 Pathology, Lippe Hospital Detmold, Röntgenstrasse 18, Detmold D-32756, Germany; E-Mail: [email protected] 5 Institute of Pathology, Mathias-Spital-Rheine, Frankenburg Street 31, Rheine D-48431, Germany; E-Mail: [email protected] 6 Institute of Pathology, Klinikum Osnabrueck, Am Finkenhuegel 1, Osnabrueck D-49076, Germany; E-Mail: [email protected] 7 Institute of Pathology, Saarbrücken-Rastpfuhl, Rheinstrasse 2, Saarbrücken D-66113, Germany; E-Mail: [email protected] 8 Department
    [Show full text]
  • Actin Binding LIM 1 (Ablim1) Negatively Controls Osteoclastogenesis by Regulating Cell Migration and Fusion
    Received: 14 September 2017 | Accepted: 16 March 2018 DOI: 10.1002/jcp.26605 ORIGINAL RESEARCH ARTICLE Actin binding LIM 1 (abLIM1) negatively controls osteoclastogenesis by regulating cell migration and fusion Haruna Narahara1,2 | Eiko Sakai1 | Yu Yamaguchi1 | Shun Narahara1 | Mayumi Iwatake1,* | Kuniaki Okamoto1,† | Noriaki Yoshida2 | Takayuki Tsukuba1 1 Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Actin binding LIM 1 (abLIM1) is a cytoskeletal actin-binding protein that has been Nagasaki University, Nagasaki, Japan implicated in interactions between actin filaments and cytoplasmic targets. Previous 2 Department of Orthodontics and Dentofacial Orthopedics, Graduate School of Biomedical biochemical and cytochemical studies have shown that abLIM1 interacts and co- Sciences, Nagasaki University, Nagasaki, Japan localizes with F-actin in the retina and muscle. However, whether abLIM1 regulates Correspondence osteoclast differentiation has not yet been elucidated. In this study, we examined the Takayuki Tsukuba, Department of Dental role of abLIM1 in osteoclast differentiation and function. We found that abLIM1 Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852- expression was upregulated during receptor activator of nuclear factor kappa-B ligand 8588, Japan. (RANKL)-induced osteoclast differentiation, and that a novel transcript of abLIM1 was Email: [email protected] exclusively expressed in osteoclasts. Overexpression of abLIM1 in the murine Funding information monocytic cell line, RAW-D suppressed osteoclast differentiation and decreased JSPS KAKENHI, Grant numbers: 15H05298, 16K15790, 17H04379 expression of several osteoclast-marker genes. By contrast, small interfering RNA-induced knockdown of abLIM1 enhanced the formation of multinucleated osteoclasts and markedly increased the expression of the osteoclast-marker genes. Mechanistically, abLIM1 regulated the localization of tubulin, migration, and fusion in osteoclasts.
    [Show full text]
  • Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 P1572 in Immune‑Mediated Models of Skin Disease Yan Xing, Katherine A
    E‑Poster Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 P1572 in Immune‑Mediated Models of Skin Disease Yan Xing, Katherine A. Chu, Jyoti Wadhwa, Wei Chen, Jiang Zhu, Jin Shu, Matthew C. Foulke, Natalie Loewenstein, Philip Nunn, Kolbot By, Pasit Phiasivongsa, David M. Goldstein, and Claire L. Langrish Principia Biopharma Inc, A Sanofi Company, South San Francisco, CA, USA • In vitro, PRN473 inhibited B‑cell activation and FcR signaling in monocytes and mast cells, and IgE‑Mediated PCA Mouse Reaction INTRODUCTION MATERIALS AND METHODS in the absence of cytotoxic effects and limited functional effects in basophils, epidermal growth factor receptor (EGFR), and cells absent BTK signaling (Table 1A) • Significant dose‑dependent inhibition of mouse PCA IgE‑mediated reaction was also observed with single and multiday • PRN473 demonstrated durable BTK inhibition at 4 h that was partially sustained through 18 h applications of PRN473 ≥1%, approaching positive controls with higher strengths up to 4% PRN473 (Figure 6) Bruton Tyrosine Kinase In Vitro Selectivity and Functional Assays (Table 1B) • Multiday (3 days) treatment achieved similar levels of inhibition with respect to single administration (data not shown) • Bruton tyrosine kinase (BTK) is a promising target in immunology because of its expression in • PRN473 1 µM was tested against a panel of 230 kinase targets in the KINOMEscan™ panel B cells and innate immune cells, providing essential downstream signaling for B‑cell receptors, Biochemical studies were performed to characterize the potency, selectivity, biochemical Table 1. Preclinical Target Specificity and BTK Occupancy for PRN473 Figure 6. Dose‑Dependent Inhibition in IgE Antibody‑Mediated Mouse Passive Fc receptors, and other innate cell pathways (Figure 1)1,2 • on‑rate and off‑rate, and reversibility of the interaction between PRN473 and BTK Cutaneous Anaphylaxis (PCA) With Single Application of PRN473 • Selective inhibition of BTK function and occupancy and off‑target effects were evaluated in A.
    [Show full text]
  • Dematin (18): Sc-135881
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . Dematin (18): sc-135881 BACKGROUND APPLICATIONS Caldesmon, Filamin 1, Nebulin, Villin, Plastin, ADF, Gelsolin, Dematin and Dematin (18) is recommended for detection of Dematin of mouse, rat and Cofilin are differentially expressed Actin binding proteins. Dematin is a human origin by Western Blotting (starting dilution 1:200, dilution range bundling protein of the erythrocyte membrane skeleton. Dematin is localized 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein to the spectrin-Actin junctions and its Actin-bundling activity is abolished (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution upon phosphorylation by cAMP-dependent protein kinase. It may also play a range 1:50-1:500). role in the regulation of cell shape, implying a role in tumorigenesis. Dematin Suitable for use as control antibody for Dematin siRNA (h): sc-105286, is a trimeric protein containing two identical subunits and a larger subunit. Dematin siRNA (m): sc-142992, Dematin shRNA Plasmid (h): sc-105286-SH, It is localized to the heart, brain, lung, skeletal muscle and kidney. The Dematin shRNA Plasmid (m): sc-142992-SH, Dematin shRNA (h) Lentiviral Dematin gene is located on human chromosome 8p21, a region frequently Particles: sc-105286-V and Dematin shRNA (m) Lentiviral Particles: delet ed in prostate cancer, and mouse chromosome 14. sc-142992-V. REFERENCES Molecular Weight of Dematin: 52/48 kDa. 1. Rana, A.P., et al. 1993. Cloning of human erythroid Dematin reveals Positive Controls: Hep G2 cell lysate: sc-2227.
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • Current Understanding of Tyrosine Kinase BMX in Inflammation and Its
    Burns & Trauma, July 2014, Vol 2, Issue 3 Review Article Current understanding of tyrosine kinase BMX in infl ammation and its inhibitors Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen Department of Burns, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China Corresponding author: Xu-Lin Chen, Department of Burns, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui 230022, China. E-mail: [email protected] Received: 14-04-14, Revised: 05-06-14, Accepted: 11-06-14 ABSTRACT Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome X (BMX), are the second largest group of non-receptor tyrosine kinases and have a highly conserved carboxyl-terminal kinase domain. BMX was identifi ed in human bone marrow cells, and was demonstrated to have been expressed in myeloid hematopoietic lineages cells, endothelial cells, and several types of cancers. Signifi cant progress in this area during the last decade revealed an important role for BMX in infl ammation and oncologic disorders. This review focuses on BMX biology, its role in infl ammation and possible signaling pathways, and the potential of selective BMX inhibitors. Key words: BMX, infl ammation, tyrosine kinase Introduction tyrosine kinase on chromosome X (BMX).[2] Tec family kinases have been the focus of immunological interest ever The response of cells to extracellular stimuli is in part medi- since their discovery. ated by a number of intracellular kinases.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]